Return to Article Details
How do varying concentrations and treatment durations of anti-PDL1 antibodies affect HCT116 cell viability, xenograft tumor size, and T cell activation, as measured by MTT assay, tumor weight, and IL-2 production, respectively?
Download
Download PDF